EUVIMEDEUVIMED entdecken
Crossref

Data support longer recurrence‐free survival with nivolumab than with ipilimumab for stage III or IV melanoma

Carrie Printz

CA: A Cancer Journal for Clinicians · 2026-05 · 76 (3)

DOI: 10.3322/caac.70085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 22.06.2026. Verfasst von Carrie Printz.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Printz, C. (2026). Data support longer recurrence‐free survival with nivolumab than with ipilimumab for stage III or IV melanoma. CA: A Cancer Journal for Clinicians, 76(3). https://doi.org/10.3322/caac.70085

Vancouver

Printz C. Data support longer recurrence‐free survival with nivolumab than with ipilimumab for stage III or IV melanoma. CA: A Cancer Journal for Clinicians. 2026;76(3). doi:10.3322/caac.70085

BibTeX
@article{Printz2026,
  author = {Printz, Carrie},
  title = {Data support longer recurrence‐free survival with nivolumab than with ipilimumab for stage III or IV melanoma},
  journal = {CA: A Cancer Journal for Clinicians},
  year = {2026},
  volume = {76},
  number = {3},
  doi = {10.3322/caac.70085}
}
Kostenlos starten →